KRT19

Across TCGA pan-cancer cohorts, KRT19 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of KRT19’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where KRT19 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types KRT19 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

PDAC, LSCC, and CCRCC are the cancer types where KRT19 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRT19 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Male	III,IV	+1.755	<.001	11	view →
LSCC	Female	All	+0.941	<.001	9	view →
CCRCC	Male	III,IV	−1.143	<.001	8	view →
LUAD	Male	II,III,IV	+0.459	<.001	6	view →
COAD	Female	IV	−1.010	.005	1	view →
HNSC	All	II,III,IV	−0.408	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

KRT19–PDAC

Open the PDAC breakdown →